Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$22.14
+2.9%
$20.72
$18.33
▼
$34.84
$70.83B0.6397,559 shs148,308 shs
Merck KGaA stock logo
MKGAF
Merck KGaA
$167.57
+0.1%
$160.41
$116.68
▼
$175.56
$21.87B0.96619 shs298 shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$21.07
+1.5%
$19.01
$13.49
▼
$21.22
$66.49B-0.023.01 million shs2.97 million shs
UCB SA stock logo
UCBJY
UCB
$159.76
+3.8%
$125.99
$110.55
▼
$168.76
$58.20B0.450,718 shs15,887 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
+2.88%+5.53%+14.74%+5.23%-1.38%
Merck KGaA stock logo
MKGAF
Merck KGaA
+0.07%+0.30%+5.59%-0.26%+33.69%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
+1.54%+4.57%+18.17%+23.73%+55.17%
UCB SA stock logo
UCBJY
UCB
+3.77%+5.92%+41.39%+23.53%+28.11%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$22.14
+2.9%
$20.72
$18.33
▼
$34.84
$70.83B0.6397,559 shs148,308 shs
Merck KGaA stock logo
MKGAF
Merck KGaA
$167.57
+0.1%
$160.41
$116.68
▼
$175.56
$21.87B0.96619 shs298 shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$21.07
+1.5%
$19.01
$13.49
▼
$21.22
$66.49B-0.023.01 million shs2.97 million shs
UCB SA stock logo
UCBJY
UCB
$159.76
+3.8%
$125.99
$110.55
▼
$168.76
$58.20B0.450,718 shs15,887 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
+2.88%+5.53%+14.74%+5.23%-1.38%
Merck KGaA stock logo
MKGAF
Merck KGaA
+0.07%+0.30%+5.59%-0.26%+33.69%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
+1.54%+4.57%+18.17%+23.73%+55.17%
UCB SA stock logo
UCBJY
UCB
+3.77%+5.92%+41.39%+23.53%+28.11%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
2.60
Moderate BuyN/AN/A
Merck KGaA stock logo
MKGAF
Merck KGaA
0.00
N/AN/AN/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
3.00
BuyN/AN/A
UCB SA stock logo
UCBJY
UCB
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest MKGAF, CHGCY, TAK, and UCBJY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/3/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
UpgradeHold (C) ➝ Hold (C+)
10/30/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
UpgradeHold ➝ Strong-Buy
10/27/2026
UCB SA stock logo
UCBJY
UCB
UpgradeHold ➝ Strong-Buy
10/8/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
UpgradeHold (C-) ➝ Hold (C)
10/1/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
DowngradeStrong-Buy ➝ Hold
9/16/2026
UCB SA stock logo
UCBJY
UCB
DowngradeStrong-Buy ➝ Hold
9/11/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
UpgradeSell (D+) ➝ Hold (C-)
9/2/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
UpgradeHold ➝ Strong-Buy
9/1/2026
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
UpgradeHold
8/6/2026
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
DowngradeStrong-Buy ➝ Hold
(Data available from 11/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$8.41B8.66$0.98 per share22.69$4.12 per share5.37
Merck KGaA stock logo
MKGAF
Merck KGaA
$22.72B0.95$50.47 per share3.32$212.00 per share0.79
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$28.32B2.38$3.15 per share6.69$14.58 per share1.44
UCB SA stock logo
UCBJY
UCB
$8.76B6.90N/AN/AN/A∞
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$2.91B$0.9622.4218.15N/A35.63%24.91%20.67%N/A
Merck KGaA stock logo
MKGAF
Merck KGaA
$3.06B$6.8125.5815.88N/A12.60%10.17%5.74%11/12/2026 (Estimated)
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
-$1.01B$0.7627.7215.05N/A8.26%11.51%5.59%N/A
UCB SA stock logo
UCBJY
UCB
$1.76BN/AN/A18.930.88N/AN/AN/AN/A

Latest MKGAF, CHGCY, TAK, and UCBJY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026N/A
Merck KGaA stock logo
MKGAF
Merck KGaA
$2.47N/AN/AN/A$6.20 billionN/A
10/27/2026Q3 2026
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
N/A$0.27N/A$0.27$2.29 billion$2.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$0.251.13%N/A26.04%N/A
Merck KGaA stock logo
MKGAF
Merck KGaA
N/AN/AN/AN/AN/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.482.28%-6.89%63.16%N/A
UCB SA stock logo
UCBJY
UCB
$0.520.33%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
N/A
4.35
3.54
Merck KGaA stock logo
MKGAF
Merck KGaA
0.27
1.31
0.84
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.56
1.15
0.60
UCB SA stock logo
UCBJY
UCB
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
0.01%
Merck KGaA stock logo
MKGAF
Merck KGaA
0.10%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
9.17%
UCB SA stock logo
UCBJY
UCB
N/A

Insider Ownership

CompanyInsider Ownership
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
N/A
Merck KGaA stock logo
MKGAF
Merck KGaA
N/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.04%
UCB SA stock logo
UCBJY
UCB
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
7,8723.29 billionN/ANot Optionable
Merck KGaA stock logo
MKGAF
Merck KGaA
62,461129.24 millionN/ANot Optionable
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
47,0003.20 billion3.20 billionOptionable
UCB SA stock logo
UCBJY
UCB
10,117378.04 millionN/ANot Optionable

Recent News About These Companies

UCB (UCBJY) Upgraded to Buy: Here's Why
UCB ADR (UCBJY) Ratios
UCB SA (UCBJY) Analyst/Investor Day Transcript
UCB ADR Stock Price History

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Chugai Pharmaceutical stock logo

Chugai Pharmaceutical OTCMKTS:CHGCY

$22.14 +0.62 (+2.88%)
As of 11/4/2026 03:59 PM Eastern

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Merck KGaA stock logo

Merck KGaA OTCMKTS:MKGAF

$167.57 +0.12 (+0.07%)
As of 11/4/2026 03:35 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Takeda Pharmaceutical stock logo

Takeda Pharmaceutical NYSE:TAK

$21.06 +0.32 (+1.52%)
Closing price 11/4/2026 03:59 PM Eastern
Extended Trading
$21.60 +0.54 (+2.54%)
As of 07:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

UCB stock logo

UCB OTCMKTS:UCBJY

$159.76 +5.81 (+3.77%)
As of 11/4/2026 03:50 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.